Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis / 临床耳鼻咽喉头颈外科杂志
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
;
(24): 201-203, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-747533
ABSTRACT
OBJECTIVE@#To investigate the efficacy and safety of polysaccharide nucleic acid-fraction (BCG-PSN) in the treatment of vasomotor rhinitis.@*METHOD@#Sixty patients were randomly divided into BCG-PSN group (n = 30) and control group (n = 30). The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months, and intranasal azelastine was used if needed. The patients in control group were administered with intranasal azelastine solely twice a day, which could be decreased with the symptom relief. Follow-up was 6 months. Symptom and medication scores were recorded. Side effects were registered.@*RESULT@#The symptom and medication scores of BCG-PSN group were significantly lower than that of control group (P 0.05), while the medication score of BCG-PSN group was still much lower than that of control group (P < 0.01). No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.@*CONCLUSION@#BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Vacuna BCG
/
Método Simple Ciego
/
Rinitis Vasomotora
/
Usos Terapéuticos
/
Quimioterapia
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Adolescente
/
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS